Divergent Survival Outcomes With Adjuvant Chemotherapy in Stage IA Ovarian Clear Cell Carcinoma: Insights From the SEER Database.

Obstet Gynecol Int · 2025 · PMC12578555 · PMID 41180797

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

For Stage IC patients, those receiving chemotherapy ( n = 744) had a favorable trend in OS compared to those not receiving chemotherapy ( n = 145), with 5-year OS rates of 85.1% and 77.5%, although the difference was not statistically significant ( p =0.116).

also in 993 other papers

did not reach statistical significanceno p-value reported

[ 18 ] indicated that adjuvant chemotherapy significantly improved the prognosis of patients with Stage IA and Stage IB ovarian cancer although the improvement for Stage IC patients did not reach statistical significance.

also in 74,032 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.